Global Custom Market Research Reports Provider Company

phone

Thalassemia - Pipeline Review, H1 2018

  • Published Date: 27 Feb 2018
  • Number of Pages: 148
  • Category: Pharmaceuticals
  • Country: Global

Thalassemia - Pipeline Review, H1 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Thalassemia - Pipeline Review, H1 2018, provides an overview of the Thalassemia (Hematological Disorders) pipeline landscape.

Thalassemia is a group of inherited blood disorders that affect the bodys ability to produce hemoglobin and red blood cells. Symptoms include fussiness, paleness, frequent infections, failure to thrive, poor appetite and jaundice. Predisposing factors include family history. Treatment includes blood transfusions and bone marrow transplant.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Thalassemia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Thalassemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thalassemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Thalassemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 7, 5, 3, 14 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 3 and 1 molecules, respectively.

Thalassemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Thalassemia (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Thalassemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Thalassemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Thalassemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Thalassemia (Hematological Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Thalassemia (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Thalassemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Publisher Name : Global Markets Direct


Introduction 4
Thalassemia - Overview 5
Thalassemia - Therapeutics Development 6
Thalassemia - Therapeutics Assessment 14
Thalassemia - Companies Involved in Therapeutics Development 22
Thalassemia - Drug Profiles 32
Thalassemia - Dormant Projects 129
Thalassemia - Product Development Milestones 130
Appendix 143



List Of Tables

List of Tables
Number of Products under Development for Thalassemia, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Thalassemia - Pipeline by Acceleron Pharma Inc, H1 2018
Thalassemia - Pipeline by Agios Pharmaceuticals Inc, H1 2018
Thalassemia - Pipeline by bluebird bio Inc, H1 2018
Thalassemia - Pipeline by Cadila Healthcare Ltd, H1 2018
Thalassemia - Pipeline by Calimmune Inc, H1 2018
Thalassemia - Pipeline by CRISPR Therapeutics, H1 2018
Thalassemia - Pipeline by Editas Medicine Inc, H1 2018
Thalassemia - Pipeline by Errant Gene Therapeutics LLC, H1 2018
Thalassemia - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
Thalassemia - Pipeline by Gamida Cell Ltd, H1 2018
Thalassemia - Pipeline by Gilead Sciences Inc, H1 2018
Thalassemia - Pipeline by Incyte Corp, H1 2018
Thalassemia - Pipeline by Ionis Pharmaceuticals Inc, H1 2018
Thalassemia - Pipeline by IRBM Science Park SpA, H1 2018
Thalassemia - Pipeline by Kiadis Pharma NV, H1 2018
Thalassemia - Pipeline by La Jolla Pharmaceutical Company, H1 2018
Thalassemia - Pipeline by Merck & Co Inc, H1 2018
Thalassemia - Pipeline by Protagonist Therapeutics Inc, H1 2018
Thalassemia - Pipeline by Sangamo Therapeutics Inc, H1 2018
Thalassemia - Pipeline by Vifor Pharma AG, H1 2018
Thalassemia - Dormant Projects, H1 2018



List Of Figures

List of Figures
Number of Products under Development for Thalassemia, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018



The global market size of Beta Thalassemia Testing is $XX million in 2017 with XX CAGR from 2013 to 2017, and it is expected to reach $XX million by the

View Report

Thalassemia - Pipeline Review, H1 2018 Summary Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Thalassemia - Pipeline Review, H1 2018, provides an overview of the

View Report

DelveInsights Thalassemia - Market Insight, Epidemiology and Market Forecast - 2027 report provides a detailed analysis of the Thalassemia epidemiology and market outlook for the 7MM. Markets Covered United

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports